ImportRefusal LogoImportRefusal

Teva API India Private Ltd.

⚠️ Moderate Risk

FEI: 3005343793 • Amroha, Uttar Pradesh • INDIA

FEI

FEI Number

3005343793

📍

Location

Amroha, Uttar Pradesh

🇮🇳

Country

INDIA
🏢

Address

A2, A-2/1, A-2/2 Upsidc Ind. Area, Bijnor Road, Gajraula, Amroha, Uttar Pradesh, India

Moderate Risk

FDA Import Risk Assessment

36.7
LowModerateHighCritical

This firm has a moderate history of FDA import refusals. Some attention may be warranted.

Statistics

9
Total Refusals
3
Unique Violations
10/4/2019
Latest Refusal
1/6/2012
Earliest Refusal

Score Breakdown

Violation Severity
61.1×40%
Refusal Volume
37.0×30%
Recency
0.0×20%
Frequency
11.6×10%
How is this score calculated?

Proprietary Algorithm

  • 40% Violation Severity — AI-assessed (1-10)
  • 30% Refusal Volume — Logarithmic scale
  • 20% Recency — Decays over 5 years
  • 10% Frequency — Refusals per year

© ImportRefusal.com Original Analysis

Violation Summary

1185×

NOT LISTED

It appears the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by section 510(j) or 510(k).

163×

DIRECTIONS

The article is subject to refusal of admission pursuant to section 801(a)(3) in that it is a device whose label appears to not bear adequate directions for use.

751×

UNAPPROVED

The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).

Refusal History

DateProductViolationsDivision
10/4/2019
62OCS24DILTIAZEM HYDROCHLORIDE (ANTI-HYPERTENSIVE - PART II)
118NOT LISTED
Division of Southeast Imports (DSEI)
10/4/2019
62OCS24DILTIAZEM HYDROCHLORIDE (ANTI-HYPERTENSIVE - PART II)
118NOT LISTED
Division of Southeast Imports (DSEI)
10/4/2019
62OCS24DILTIAZEM HYDROCHLORIDE (ANTI-HYPERTENSIVE - PART II)
118NOT LISTED
Division of Southeast Imports (DSEI)
10/4/2019
62OCS24DILTIAZEM HYDROCHLORIDE (ANTI-HYPERTENSIVE - PART II)
118NOT LISTED
Division of Southeast Imports (DSEI)
10/4/2019
62OCS24DILTIAZEM HYDROCHLORIDE (ANTI-HYPERTENSIVE - PART II)
118NOT LISTED
Division of Southeast Imports (DSEI)
4/6/2017
61ECS09MONTELUKAST SODIUM (ANTI-ASTHMATIC)
16DIRECTIONS
Division of Northeast Imports (DNEI)
4/6/2017
61ECS09MONTELUKAST SODIUM (ANTI-ASTHMATIC)
16DIRECTIONS
Division of Northeast Imports (DNEI)
4/6/2017
61ECS09MONTELUKAST SODIUM (ANTI-ASTHMATIC)
16DIRECTIONS
Division of Northeast Imports (DNEI)
1/6/2012
64BCB25HYDROCHLOROTHIAZIDE (DIURETIC)
75UNAPPROVED
New Orleans District Office (NOL-DO)

Frequently Asked Questions

What is Teva API India Private Ltd.'s FDA import refusal history?

Teva API India Private Ltd. (FEI: 3005343793) has 9 FDA import refusal record(s) in our database, spanning from 1/6/2012 to 10/4/2019.

What is an FEI number?

FEI stands for Firm Establishment Identifier. It's a unique number assigned by the FDA to identify establishments that manufacture, process, pack, or hold food, drugs, medical devices, or other FDA-regulated products. Teva API India Private Ltd.'s FEI number is 3005343793.

What types of violations has Teva API India Private Ltd. received?

Teva API India Private Ltd. has been cited for 3 different violation type(s). Common FDA violations include adulteration (unsafe or unsanitary products), misbranding (incorrect or misleading labels), and regulatory non-compliance.

Where does this information about Teva API India Private Ltd. come from?

All FDA import refusal data for Teva API India Private Ltd. is sourced from the official FDA Data Dashboard (datadashboard.fda.gov), a public government database maintained by the U.S. Food and Drug Administration.

Data sourced from the FDA Data Dashboard, a public database maintained by the U.S. Food and Drug Administration.